Location & dates EMBL Heidelberg, Germany 2 - 4 Feb 2017
Deadlines Registration closed Abstract submission closed


The poster listings can be downloaded here.

A pdf document of the final programme can be downloaded here.

Got something to say? Share it with #ECCEimmuno

Day 1 - Thursday 2 February 2017
12:00-13:30 Registration and light refreshments
13:30-13:45 Opening remarks
13:45-17:30 Session 1: Unleashing endogenous immunity
Chair: Christof von Kalle

Ugur Sahin, Johannes Gutenberg University Mainz


Heterogeneity and dynamics of the tumor-infiltrating lymphocyte repertoire
Isabel Poschke, DKFZ


NOX2-derived oxidative stress promotes melanoma metastasis by inhibiting IFN-gamma producing NK cells
Ebru Aydin, Gothenburg University


Coffee Break kindly sponsored by Roche


T cell differentiation in chronic infection
Dietmar Zehn, Technical University Munich

15:45-16:15 Targeting the driver mutation IDH1R132H in brain tumors
Michael Platten, German Cancer Research Institute
16:15-17:00 Coffee Break (kindly sponsored by Roche) & Meet the Speakers
17:00-17:30 What do T cells recognize on tumor cells?
John Haanen, Netherlands Cancer Institute

Flash talks (1 slide / 2 min each):
Kroon #51, Thiesen #61, Veerman #63, Volkmar #65, Younos #67

17:45-19:00 Poster Session I (odd numbers)
19:00-20:30 Welcome reception with light refreshments
Day 2 - Friday 3 February 2017
09:00-12:00 Session 2: Clinical studies of T cell-based immunotherapies
Chair: Dirk Jäger
09:00-09:30 T Cell-engaging Antibodies for Cancer Therapy
Patrick Baeuerle, MPM Capital
09:30-09:45 High mutational load drives durable remission by targeting programmed death receptor 1 in a patient with metastatic luminal breast cancer
Carlo Fremd, NCT

What do we need for Successful Adoptive Immunotherapy of Solid Tumors?
Malcolm Brenner, Texas Children´s Hospital

10:15-10:45 Coffee Break kindly sponsored by Roche
10:45-11:15 Immune Checkpoint Blockade in treatment of advanced Melanoma
Dirk Schadendorf, University Hospital Essen
11:15-11:45 Ton Schumacher, The Netherlands Cancer Institute

Immune evasion and PD-1-positive T cell infiltration in DNA mismatch repair-deficient colorectal cancer
Matthias Kloor, University Hospital Heidelberg

12:00-13:45 Lunch
13:45-17:30 Session 3: Markers of effective immune responses

TCR gene editing of memory stem T cells for cancer treatment
Chiara Bonini, Ospedale San Raffaele - Milano


Jérôme Galon, INSERM


AT1413: an antibody isolated from a cured Acute Myeloid Leukemia (AML) patient that is highly efficacious against AML in vivo
Greta de Jong, AIMM Therapeutics

15:00-15:30 Genomic analysis of human tumor immunity
Nir Hacohen, Massachusetts General Hospital, Harvard Medical School

Coffee Break (kindly sponsored by Roche) & Meet the Speakers


Investigation of tumor-reactive T-cell repertoire in the immune infiltrate of metastatic melanoma under immune checkpoint inhibition
Jessica Hassel, University Hospital Heidelberg


Immunotherapy for melanoma patients: towards identification of predictive response biomarkers
Michal Harel, Tel Aviv University


AML patients cured after allogeneic hematopoietic stem cell transplantation develop antibodies capable of directly killing AML blasts in vitro and in vivo
Gemma Moiset, AIMM Therpeutics


Modulating T cell metabolism for cancer immunotherapy
Roger Geiger, Institute for Research in Biomedicine

17:30-17:45 Flash talks (1 slide / 2 min each):
Kather #48, Krall #50, Schneidt #58, Tunali #62

Poster Session II (even numbers)

19:00-21:00 Banquet Dinner
21:00-00:00 Conference Party with DJ
Day 3 - Saturday 4 February 2017
09:00-12:15 Session 4: Inducing Immunity
Chair: Ton Schumacher

09:00-09:30 T cell therapies for Hematologic Cancers – Beyond CARs
Catherine M. Bollard, Children's National Health System

Oncolytic Measles Virus for Tumor-Specific Vaccination
Christine Engeland, NCT


Development of rational immunomodulation strategies for virotherapy
Ruta Veinalde, NCT


Adoptive T cell therapy
Thomas Blankenstein, Max-Delbrück Center for Molecular Medicine


Coffee Break (kindly sponsored by Roche) & Meet the Speakers


BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
Johannes Heidbuechel, DKFZ

11:15-11:30 The molecular basis of CD4+ T-cell help for the cytotoxic T-cell response against cancer
Tomasz Ahrends, Netherlands Cancer Institute
11:30-11:45 Direct detection of predicted tumor neoepitopes by targeted mass spectrometry
Angelika Riemer, DKFZ
11:45-12:15 Crosstalk between the adaptive and innate immune system in metastatic breast cancer
Karin de Visser, Netherlands Cancer Institute
12:15-14:00 Lunch
14:00-17:15 Session 5: Targeting the microenvironment
Chair: Hans-Reimer Rodewald


Anti-tumor T cells- you are what you eat
Susan Kaech, Yale School of Medicine


The mechanistic basis of cancer immunotherapy
Ira Mellman, Genentech


Myeloid Derived Suppressor Cells-Mast Cells Cross-Talk Via C40-CD40L Mediate Tumor Specific Immunosuppression in Prostate Cancer
Elena Jachetti, Fondazione IRCCS

15:15-15:30 Hypoxia induces a new population of tumor-reactive CD8 T cells expressing high levels of PD-1 and IL-10
Telma Lanca, Netherlands Cancer Institute
15:30-16:00 Coffee Break kindly sponsored by Roche

Inflammation-induced phenotypic plasticity of tumor and immune cells in disease progression and therapy resistance of melanoma
Thomas Tüting, University of Magdeburg


Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections
Bjoern Wendik, PerkinElmer


The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas
Jana Sonner, DKFZ

17:00-17:15 Closing remarks
17:25 Bus departure to downtown Heidelberg & Frankfurt Int. Airport
(tickets for the airport bus are available for 25 EUR at the registration desk)